Citizens JMP downgraded Vor Bio (VOR) to Market Perform from Outperform without a price target Vor is exploring strategic alternatives and ended all development programs based on currently available clinical data from its key clinical programs and a challenging fundraising environment, the analyst tells investors in a research note. The firm views the shares as trading at fair value.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VOR: